La Flaca
4 minutes ago
I agree it's a silly debate, and that what matters is that EMA/FDA will review their applications on the totalilty of the circumstances. This is also why the argument about Anavex publicly stating they met two endpoints, vs. one, is also silly, imo. It is concerning as a shareholder, but EMA/FDA don